Severe pneumonia with formation of a pulmonary cavity associated with long-term rituximab therapy in multiple sclerosis
Abstract Nowadays B-cell depletion via anti-CD20 antibodies is commonly applied in the treatment of multiple sclerosis (MS). Yet, not much is known about infection risks associated with long-term B-cell depletion in the specific context of MS. We present the case of a 45-year-old male patient who de...
Main Authors: | Carolin Schwake, Ralf Gold |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2020-10-01
|
Series: | Neurological Research and Practice |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s42466-020-00074-0 |
Similar Items
-
Cyclophosphamide Versus Rituximab in Progressive Forms of Multiple Sclerosis
by: Masoud Etemadifar, et al.
Published: (2020-02-01) -
Effects of treatment with rituximab on microcirculation in patients with long-term systemic sclerosis
by: Verônica Silva Vilela, et al.
Published: (2018-12-01) -
Destructive pulmonary fibrosis after severe COVID-19 pneumonia
by: Alice Letellier, et al.
Published: (2020-11-01) -
Rituximab in Multiple Sclerosis: Are We Ready for Regulatory Approval?
by: Serena Brancati, et al.
Published: (2021-07-01) -
Rituximab for the therapy of systemic sclerosis: a series of 10 cases in a single center
by: Verônica Silva Vilela, et al.